Chemotherapy drugs are still one of the first treatment options used in many
cancers; however, problems such as cytotoxic side effects on normal cells after systemic administration and resistance to treatment have reduced the use of chemotherapeutics day by day. Targeted delivery of these drugs to the
tumor site and sensitization of
cancer cells to death induced by
chemotherapy drugs are ways that can overcome the limitations of the use of these drugs. In this study, we designed and generated a novel nanocarrier composed of
chitosan lactate nanoparticles (NPs) functionalized by HIV-1 derived TAT
peptide (Transactivating transcriptional activator) and hyaluronate (HA) to deliver CD73
siRNA and
doxorubicin to 4T1 and CT26
cancer cells, both in vivo and in vitro, as a novel combinatorial treatment strategy. The CD73 molecule plays a key role in many
cancer cell behaviors such as proliferation, angiogenesis,
metastasis, imunosuppression, and resistance to
chemotherapy. Therefore, we decided to reduce the side effects of DOX by simultaneously transmitting CD73
siRNA and DOX by CL-TAT-HA NPs, increase the susceptibility of
cancer cells to DOX-induced cell death, and stimulate anti-
tumor immune responses, for the first time. These results indicated that simultaneous transfer of CD73
siRNA and DOX to
cancer cells (4 T1 and CT26) increased cell death and inhibited the prolifration and spread of
cancer cells. Also, the preferential aggregation of NPs in the tumor microenvironment reduced
tumor growh, promoted the survival of
tumor-bearing mice, and induced anti-
tumor immune responses. These findings indicate that CL-TAT-HA NPs are a good candidate for targeted
siRNA/drug delivery to
cancer cells and the simultaneous transfer of CD73
siRNA and DOX to
cancer cells using this nanocarrier can be used to treat
cancer.